A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty